ReviewDigestive diseases and sciences2026
Navigating the Prognosis and Functional Recovery of Short Bowel Syndrome: A Mentored Review.
Review in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Short bowel syndrome (SBS) is a debilitating condition resulting from extensive small bowel resection, leading to profound malabsorption, malnutrition, and complications due to reduced absorptive capacity. The remaining intestine undergoes a complex process of intestinal adaptation, characterized by varying degrees of adaptive changes among individuals. While some patients regain oral autonomy, others will go on to develop chronic intestinal failure, necessitating long-term dependence on parenteral nutrition. This review outlines the different phases of intestinal adaptation-acute, adaptation, and maintenance-and current evidence-based interventions at each stage. This article also highlights prognostic factors that influence bowel recovery. Emerging biomarkers, including citrulline, apoprotein A-IV, and glucagon-like peptide 2, are evaluated for their potential in guiding treatment decisions and monitoring intestinal adaptation. These novel biomarkers offer promising avenues for improving patient management and prognosis in SBS.
Indexed as
Identifiers
41107666What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.